Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Memantine HCl Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Down Syndrome Memantine Follow-up Study

NCT02304302
View directory record Official record
Conditions
Down Syndrome, Intellectual Disability
Interventions
Memantine, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
15 Years to 32 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

NCT02580305
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SUVN-502, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease

NCT00646204
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Memantine, placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia

NCT00545974
View directory record Official record
Conditions
Frontal Lobe Dementia, Frontotemporal Lobe Dementia, Semantic Dementia
Interventions
memantine, Placebo pill
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

NCT01555697
View directory record Official record
Conditions
Schizophrenia
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 21, 2026, 4:14 PM EDT
Active, not recruiting Phase 3 Interventional

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

NCT04804644
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
227
States / cities
Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 4 Interventional

Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease

NCT00305903
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine, memantine
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder

NCT00674219
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Generalized Anxiety Disorder
Interventions
Memantine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 21, 2026, 4:14 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine

NCT03858270
View directory record Official record
Conditions
Parkinson Disease
Interventions
Memantine, Placebo
Drug · Other
Lead sponsor
Wayne State University
Other
Eligibility
45 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

NCT02079246
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Idalopirdine 60 mg
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
1,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus

NCT00928954
View directory record Official record
Conditions
Nystagmus
Interventions
gabapentin, memantine
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Naltrexone and Memantine Effects on Alcohol Drinking Behaviors

NCT01519063
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Naltrexone and memantine first, Naltrexone and Placebo first
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression

NCT00305578
View directory record Official record
Conditions
Bipolar Depression
Interventions
Memantine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Memantine Augmentation of Antidepressants

NCT00344682
View directory record Official record
Conditions
Depressive Disorder
Interventions
memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 21, 2026, 4:14 PM EDT
Active, not recruiting Early Phase 1 Interventional

Memantine for Enhanced Stroke Recovery

NCT02144584
View directory record Official record
Conditions
Ischemic Stroke, Upper Extremity Weakness
Interventions
Memantine XR, Placebo (for memantine)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 2Phase 3 Interventional

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

NCT00300716
View directory record Official record
Conditions
Multiple Sclerosis, Cognition Disorders
Interventions
Memantine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

NCT04033419
View directory record Official record
Conditions
Cognitive Decline, Chemo-brain
Interventions
Memantine
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 21, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

NCT06041789
View directory record Official record
Conditions
Osteoporosis
Interventions
Donepezil, Memantine
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 21, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional Results available

Memantine for Recurrent Glioblastoma

NCT01260467
View directory record Official record
Conditions
Glioblastoma
Interventions
memantine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients

NCT00255086
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memantine, Placebo pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 95 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 21, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

NCT06789757
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Memantine Hydrochloride, Bevacizumab, Atezolizumab
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

NCT00411398
View directory record Official record
Conditions
General Anxiety Disorder, Social Anxiety Disorder
Interventions
Namenda/Memantine
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Sep 21, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional

Pattern Separation in Major Depressive Disorder

NCT07139834
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo
Drug
Lead sponsor
Jeffrey Miller
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 21, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Pilot Clinical Trial Of Memantine for Essential Tremor

NCT00439699
View directory record Official record
Conditions
Essential Tremor
Interventions
Memantine
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Sep 21, 2026, 4:14 PM EDT